Austar Lifesciences Limited provided group earnings guidance for the six months ending June 30, 2017. The board of directors of the company inform the shareholders of the company and potential investors that, based on information currently available, the group is expected to record a substantial increase in loss attributable to the shareholders of the company for the six months ending 30 June 2017 as compared to a loss attributable to the shareholders of the company of approximately RMB 12.1 million for the corresponding period in 2016. Such loss is mainly attributable to an increase in budgeted costs mainly due to prolonged execution time for certain projects undertaken by the group resulting in decrease in gross profit of the Group; substantial decrease in revenue from the liquid and bioprocess segment which is the major revenue contributor of the group as compared with the corresponding period in 2016; and certain projects with lower gross profit margin were executed during the period in an attempt to secure orders for increasing the market share of the bioprocess market as well as retaining long term customers. Nonetheless, the effect of such decrease is partially offset by a substantial increase in revenue from the life science consumables segment of the Group.